Industry: Health care Region: Austria Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A health technology company in Austria, together with many well-known medical schools in Europe, has built an intelligent diagnosis and treatment platform. Relying on AI technology to integrate clinical and biological data can screen immune-related diseases such as cancer, autoimmune diseases and transplant rejection in advance, which can not only help hospitals reduce patient mortality, shorten hospitalization period, save treatment costs, but also help pharmaceutical companies accelerate the research and development of new drugs and optimize clinical trials. The platform conforms to the EU data security standards, and can directly connect with the existing hospital systems. The team has many research results of international medical journals and deep cooperation with many authoritative European medical institutions.
Core products:
An integrated online diagnosis and treatment analysis platform supports functions such as data integration, disease early screening, patient risk stratification, and new drug scheme mining.
1. The use benefits are obvious, and the medical cost is greatly reduced;
2. At the same time, it adapts to the two major scenarios of hospital clinical and pharmaceutical research and development;
3. The system access is simple, and there is no need for large-scale transformation of hospital equipment;
4. Endorsed by the research teams of European universities, the technology is mature and reliable.
Application scenario:
Hospital oncology department, immunology department, transplantation department, pharmaceutical research and development enterprises, medical research institutions.
Cooperation mode:
Seeking cooperation from hospitals, medical device companies, pharmaceutical companies and scientific research institutes can provide platform landing, joint research and development, and clinical supporting technical services.